Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3079676 | 0.85 | CA1 (0.44) | MAPTGAACA1CA2TDP1 | |
| SCHEMBL21509796 | 0.85 | CES2 (0.50) | GAAKMT2AMEN1CES2CES1 | |
| SCHEMBL24310073 | 0.84 | PTPN1 (0.55) | KMT2AMEN1 | |
| SCHEMBL2241024 | 0.84 | CA1 (0.48) | MAPTGAACA1CA2KCNH2 | |
| SCHEMBL17410238 | 0.84 | CA1 (0.48) | CA1CA2TDP1DRD2KDM4E | |
| SCHEMBL14736142 | 0.84 | ALDH1A1 (0.58) | MAPTGAAHTR1AADRA2ADRD1 | |
| SCHEMBL1929771 | 0.83 | SIGMAR1 (0.52) | MAPTGAACA1CA2KMT2A | |
| SCHEMBL3571655 | 0.82 | CA1 (0.47) | MAPTGAACA1CA2KMT2A | |
| SCHEMBL14366353 | 0.81 | MAPT (0.48) | MAPTCA1CA2TDP1DRD2 | |
| SCHEMBL8242151 | 0.81 | CTNNB1 (0.52) | MAPTKMT2AMEN1DRD2CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-15 | — | — | US | disclosed |
| WO-2020039027-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| CN-104470918-A | Aromatic heterocyclic derivative and pharmaceutical | NIPPON SHINYAKU CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-7807691-B2 | Substituted N-arylpyrrolidines as selective androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807691-B2 | Substituted N-arylpyrrolidines as selective androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807691-B2 | Substituted N-arylpyrrolidines as selective androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1891038-B1 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1891038-B1 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | ELI LILLY AND COMPANY | 2008-07-24 | — | — | US | disclosed |
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | ELI LILLY AND COMPANY | 2008-07-24 | — | — | US | disclosed |
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | ELI LILLY AND COMPANY | 2008-07-24 | — | — | US | disclosed |
| EP-1891038-A2 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006124447-A2 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | PREP, GAA, DNPEP | MAPT 22/4885GAA 2/4885CA1 288/4885 |
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | AR, FSHR, SHBG | MAPT 3301/4885GAA 2760/4885CA1 4790/4885 |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | PREP, GAA, DNPEP | MAPT 24/4885GAA 2/4885CA1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.